rAAV2 Ependymal Cell Infection for CNS Protein Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in effectively treating central nervous system (CNS) diseases, such as lysosomal storage diseases, due to the blood-brain barrier preventing protein delivery and limited distribution within the brain.
Innovation Solution
Administration of recombinant AAV2 particles encoding therapeutic proteins to the cerebrospinal fluid (CSF) to infect ependymal cells, which secrete the proteins into the CSF and brain, thereby treating CNS diseases like lysosomal storage diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If therapeutic proteins are delivered intravenously to treat CNS diseases, then the proteins can reach the bloodstream, but they cannot cross the blood-brain barrier to reach the brain tissue
Solution Approach 1:
The patent uses ependymal cells as intermediary vehicles to transport therapeutic proteins across the blood-brain barrier. These cells are naturally located at the interface between the bloodstream and brain tissue, and the invention modifies them to express and secrete therapeutic proteins directly into the CNS, bypassing the barrier function of the blood-brain barrier.
Solution Approach 2:
The invention replaces the mechanical/physical delivery method (intravenous injection) with a biological delivery system (genetically modified ependymal cells) that can naturally navigate and deliver proteins to the target location within the CNS.
2Quantity of substance
If therapeutic proteins are delivered directly to the brain, then they can reach the target tissue, but they are not widely distributed throughout the brain regions
Solution Approach 1:
The ependymal cells serve multiple functions: they are infected by the viral vector to express therapeutic proteins, they secrete these proteins into the CSF, and they enable widespread distribution throughout all brain regions via CSF circulation. This single cell type performs multiple roles in the delivery system.
Solution Approach 2:
The invention utilizes the cerebrospinal fluid (CSF) circulation system as a hydraulic distribution network to transport therapeutic proteins from the site of injection to widespread brain regions, leveraging the natural flow dynamics of CSF to achieve broad distribution.
3Quantity of substance
If recombinant AAV2 particles are administered to CSF to infect ependymal cells, then therapeutic proteins can be delivered to brain regions, but the method requires specific viral vectors and administration protocols
Solution Approach 1:
The recombinant AAV2 virus particles serve as intermediary vectors that carry the genetic material into ependymal cells. These viral mediators facilitate the transfer of therapeutic genes to the target cells, which then produce and secrete the therapeutic proteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves significant enzyme activity in brain regions and improves cognitive functions in animal models, demonstrating a viable route for delivering therapeutic proteins across the blood-brain barrier and treating CNS disorders.
Implementation Method 1
an rAAV2 particle comprising an AAV2 capsid protein and a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner effective to infect an ependymal cell
Implementation Method 2
the ependymal cell secretes the therapeutic protein so as to treat the disease
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides methods of treating a disease in a non-rodent mammal comprising administering to the cerebrospinal fluid (CSF) of the non-rodent mammal an rAAV2 particle comprising an AAV2 capsid protein and a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner effective to infect an ependymal cell in the non-rodent mammal, wherein the ependymal cell secretes the therapeutic protein so as to treat the disease